| Nov 5 |
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
|
| Nov 2 |
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 1 |
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
|
| Nov 1 |
Vir Biotechnology Q3 2024 Earnings Preview
|
| Nov 1 |
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago
|
| Nov 1 |
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
|
| Nov 1 |
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
|
| Oct 31 |
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
|
| Oct 31 |
Vir Biotechnology GAAP EPS of -$1.56 misses by $0.60, revenue of $2.38M misses by $3.13M
|
| Oct 31 |
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
